All In Biotech

Drug Trial Radar · NCT05652335

A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis

Phase 1, First-in-Human, Dose Escalation Study of JNJ-79635322, a Trispecific Antibody, in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated AL Amyloidosis

Last checked: Nov 20, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

180

Planned (sponsor's estimate)

Start

Nov 22, 2022

Primary completion

Apr 19, 2027

Study completion Nov 15, 2030

Sponsor

Lead sponsor
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
Sponsor type
Industry
First posted
Dec 15, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary purpose of this study is to identify the recommended phase 2 dose (RP2D\[s\]) and schedule(s) to be safe for JNJ-79635322 in Part 1 (dose escalation), and to characterize the safety and tolerability of JNJ-79635322 at the RP2D(s) selected and in disease subgroups in Part 2 (dose expansion).

Conditions

  • Relapsed or Refractory Multiple Myeloma
  • Previously Treated Amyloid Light-chain (AL) Amyloidosis

Interventions

  • JNJ-79635322Drug

    JNJ-79635322 will be administered as SC injection.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part 1: Number of Participants with Dose-limiting Toxicity (DLT)Time frame: Up to 2 years 5 months
  2. Parts 1 and 2: Number of Participants with Adverse Events (AEs) by SeverityTime frame: Up to 2 years 5 months
  3. Part 2: Number of Participants with Abnormalities in Laboratory ValuesTime frame: Up to 2 Years 5 months

Locations

29 sites in 7 countries. Site status is shown where the registry gives one.

  • City of Hope

    Duarte, California · Recruiting

  • City of Hope Orange County Lennar Foundation Cancer Center

    Irvine, California · Recruiting

  • University of California San Francisco

    San Francisco, California · Recruiting

  • Colorado Blood Cancer Institute

    Denver, Colorado · Recruiting

  • Icahn School of Medicine at Mt. Sinai

    New York, New York · Recruiting

  • Memorial Sloan Kettering Cancer Center

    New York, New York · Recruiting

  • Levine Cancer Institute

    Charlotte, North Carolina · Recruiting

  • University of Pennsylvania Division of Hematology Oncology Perelman Center for Advanced Medicine

    Philadelphia, Pennsylvania · Recruiting

  • MD Anderson Cancer Center

    Houston, Texas · Recruiting

  • UZ Antwerpen

    Edegem, Belgium · Recruiting

  • UZ Gent

    Ghent, Belgium · Recruiting

  • CHU de Liege

    Liège, Belgium · Recruiting

  • CHU Nantes

    Nantes, France · Recruiting

  • CHU Lyon Sud

    Pierre-Bénite, France · Recruiting

  • Chu Rennes Hopital Pontchaillou

    Rennes, France · Completed

  • Institut Claudius Regaud

    Toulouse, France · Recruiting

  • Japanese Red Cross Medical Center

    Shibuya City, Japan · Active not recruiting

  • Osaka University Hospital

    Suita-shi, Japan · Active not recruiting

  • The Cancer Institute Hospital of JFCR

    Tokyo, Japan · Completed

  • VUMC Amsterdam

    Amsterdam, Netherlands · Recruiting

  • Universitair Medisch Centrum Groningen

    Groningen, Netherlands · Recruiting

  • UMC Utrecht

    Utrecht, Netherlands · Recruiting

  • Hosp. Univ. Germans Trias I Pujol

    Badalona, Spain · Recruiting

  • Hosp Clinic de Barcelona

    Barcelona, Spain · Recruiting

  • Hosp Univ Fund Jimenez Diaz

    Madrid, Spain · Recruiting

  • Clinica Univ. de Navarra

    Pamplona, Spain · Recruiting

  • Hosp Clinico Univ de Salamanca

    Salamanca, Spain · Recruiting

  • University College Hospital

    London, United Kingdom · Recruiting

  • Royal Marsden Hospital

    Sutton, United Kingdom · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.